Lyell Immunopharma Q3 EPS $(1.86) Beats $(2.06) Estimate, Sales $3.000K Beat $2.333K Estimate
Benzinga Newsdesk 10 hours ago
NewsEarningsEarnings Beats
Lyell Immunopharma (NASDAQ:LYEL) reported quarterly losses of $(1.86) per share which beat the analyst consensus estimate of $(2.06) by 9.71 percent. This is a 12.68 percent increase over losses of $(2.13) per share
Lyell Immunopharma (NASDAQ:LYEL) reported quarterly losses of $(1.86) per share which beat the analyst consensus estimate of $(2.06) by 9.71 percent. This is a 12.68 percent increase over losses of $(2.13) per share from the same period last year. The company reported quarterly sales of $3.000 thousand which beat the analyst consensus estimate of $2.333 thousand by 28.57 percent. This is a 80.00 percent decrease over sales of $15.000 thousand the same period last year.